D

*click LINK for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Dabigatran etexilate (Pradaxa®) (995/14)	DVT and PE	Non-formulary - absence of clinician demand	142	Oct/Nov 2014
Dabigatran etexilate (Pradaxa®) (672/11)	For the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more of the following risk factors: - previous stroke, transient ischaemic attack, or systemic embolism - left ventricular ejection fraction <40% - symptomatic heart failure, ≥ New York Heart Association (NYHA) Class 2 - age ≥75 years - age ≥65 years associated with one of the following: diabetes mellitus, coronary artery disease or hypertension	Non-formulary - alternatives preferred	127 (update) 125 123 (update) 112 110 109 85 80	May 2013 Mar/Apr 2013 Jan 2013 Dec 2011 Oct 2011 Sep 2011 Dec 2008 June 2008
Dabrafenib dispersible tablets (Finlee®) SMC2667	In combination with trametinib (Spexotras®) for: • the treatment of paediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. • the treatment of paediatric patients aged 1 year and older with high-grade glioma with a BRAF V600E mutation who have received at least one prior radiation and / or chemotherapy treatment.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Dabrafenib 50mg and 75mg hard capsules (Tafinlar®)	In combination with trametinib for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600	Available in line with local guidance for prescribing.	174	May 2019

SMC2131	mutation, following complete resection.			
Dabrafenib (Tafinlar®) (1023/15)	Monotherapy treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. SMC Restriction: for use in patients with unresectable or metastatic BRAFV600 mutation-positive metastatic melanoma who have received no prior therapy.	HOSPITAL ONLY - (Oncology) Supplied via a Patient Access Scheme	146	Mar 2015
Daclatasvir (Daklinza®) (1002/14)	In combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults. SMC Restriction: use is restricted to patients with significant fibrosis (Metavir scores F3-F4) or compensated cirrhosis.	Formulary HOSPITAL ONLY - Hepatitis Team	143	Nov/Dec 2014
Daclizumab 150mg/mL solution for injection in prefilled syringe/pen (Zinbryta®) (1216/17)	For use in patients with rapidly evolving severe (RES) relapsing remitting multiple sclerosis (RRMS) or in patients with RRMS with an inadequate response to disease modifying therapy. SMC Restriction: for use in patients with rapidly evolving severe (RES) relapsing remitting multiple sclerosis (RRMS) or in patients with RRMS with an inadequate response to disease modifying therapy	Discontinued - product license has been withdrawn [April 2018] MHRA Risk of severe liver injury with daclizumab, July 2017	161	Jun 2017
Dacomitinib 15mg, 30mg and 45mg film-coated tablets (Vizimpro®) SMC2184	As monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.	Available in line with local guidance for prescribing	177	Dec 2019
Dalbavancin 500mg powder for concentrate for solution for infusion (Xydalba®) (1105/15)	Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. SMC Restriction: for second-line use or when meticillin-resistant Staphylococcus aureus (MRSA) infection is suspected, or on the advice of local microbiologists or specialists in infectious disease, and the patient is initially hospitalised due to ABSSSI, requires intravenous antibiotics, but is eligible for early discharge as soon as their medical	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts – decision expected by April 2017	159	Feb 2017

	condition does not require further inpatient treatment			
Dalteparin sodium (Fragmin®) (683/11)	VTE	GPs may prescribe under the direction of the Oncology or Haematology Clinic	123 (update) 104	Jan 2013 Mar 2011
Danicopan film-coated tablets (Voydeya®) SMC2675	As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. SMC restriction: under the advice of the national PNH service. In a randomised phase III study, danicopan, as an add-on treatment to C5 inhibitor, was associated with a statistically significant improvement in haemoglobin concentrations at week 12 compared with placebo.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
dapagliflozin film-coated tablets (Forxiga®) SMC2763	In adults for the treatment of chronic kidney disease (CKD). SMC restriction: in patients having individually optimised standard care (including angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, unless these are contraindicated or not tolerated), and either, at the start of treatment: • an estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73m2 up to 45 mL/min/1.73m2, or • an eGFR of 45 mL/min/1.73m2 up to 90 mL/min/1.73m2 and either: o A urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more, or o Type 2 Diabetes Mellitus (T2DM). Dapagliflozin offers an additional treatment choice in the therapeutic class of sodium-glucose co-transporter 2 (SGLT2) inhibitor.			

dapagliflozin film-coated tablets (Forxiga®) SMC2577	in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) >40%.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	194	September 2023
Dapagliflozin 10mg film-coated tablets (Forxiga®) SMC2428	in patients with an estimated glomerular filtration rate of ≥25 to ≤75 ml/min/1.73m2 at treatment initiation, who are receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker (unless these are not tolerated or contraindicated), and have a urine albumin-creatinine ratio of at least 23mg/mmol and/or type 2 diabetes mellitus.	Available in line with national guidance	189	May 2022
Dapagliflozin 10mg film-coated tablets (Forxiga®) SMC2322	Indication under review: in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. In a randomised, double-blind, phase III study, dapagliflozin demonstrated a significant reduction in the composite outcome of hospitalisation for heart failure, urgent heart failure visit and cardiovascular death compared with placebo in patients with heart failure with reduced ejection fraction receiving current standard of care.	available in line with national guidance	184	May 2021
Dapagliflozin plus metformin (Xigduo®) (983/14)	In adults aged 18 years and older with type 2 diabetes mellitus	Formulary	140	Jul/Aug 2014
Dapagliflozin (Forxiga®) (799/12)	To improve glycaemic control in adults aged 18 years and older with type 2 diabetes mellitus	Formulary GP under the direction of Diabetes team (Formulary - restricted use in	140 136 124	Jul/Aug 2014 Mar/Apr 2014 Feb 2013

		combination with metformin)		
Dapagliflozin 5mg film coated tablets (Forxiga®) SMC2185	In adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥27kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is local preference for alternative medicines.	177	Dec 2019
Dapoxetine hydrochloride (Priligy®) (987/14)	Premature ejaculation (PE) in adult men aged 18 to 64 years	Not recommended	140	Jul/Aug 2014
Daptomycin (Cubicin®) (449/08)	Complicated skin and soft tissue infections (eSSTIs) in adults	HOSPITAL ONLY	79 77 65 57	May 2008 Mar 2008 Jan 2007 2006
Daptomycin powder for concentrate for solution for injection or infusion (Cubicin®) 1141/16	Treatment of paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections.	Not available as not recommended for use in NHS Scotland	154	May 2016
Daratumumab solution for injection and concentrate for solution for infusion (Darzalex®) SMC2536	in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	December 2023
Daratumumab 1,800mg solution for injection (Darzalex®) SMC2447	In combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. In a phase III study in patients with newly diagnosed AL amyloidosis with at least one affected organ, the addition of	Available in line with national guidance	190	August 2022

	daratumumab to bortezomib, cyclophosphamide and dexamethasone was associated with a significant improvement in complete haematologic response rate.			
Daratumumab 20mg/ml concentrate for solution for infusion and 1,800mg solution for injection (Darzalex®) SMC2416	In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. In an open-label, phase III study, the addition of daratumumab to bortezomib, melphalan, and prednisone was associated with a significant improvement in progression-free survival.		189	May 2022
Daratumumab 1,800 mg solution for injection (Darzalex®) SMC2469	In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy.	Not available as not recommended for use in NHS Scotland	188	April 2022
Daratumumab 1,800mg solution for subcutaneous injection (Darzalex®) SMC2326	Indication under review: in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. Following a submission under the orphan medicine process, SMC has previously accepted daratumumab concentrate for solution for infusion in combination with bortezomib, thalidomide and dexamethasone is indicated for the treatment	Available in line with local guidance for prescribing	183	March 2021

	of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (SMC2302).			
Daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®) SMC2302	Indication under review: in combination with bortezomib, thalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. The addition of daratumumab to bortezomib, thalidomide and dexamethasone was associated with a significant improvement in stringent complete response rates in patients with newly diagnosed multiple myeloma who were eligible for autologous stem cell transplant. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.	Available in line with local guidance for prescribing NOTE - SMC informed Jan 2025, that they will not assess the same regime with lenalidomide rather than thalidomide as it has been assessed as a minor change.	183	March 2021
Daratumumab 1,800mg solution for subcutaneous injection (Darzalex®) SMC2304	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. SMC restriction: for use as a fourth-line treatment option	Available in line with national guidance	181	November 2020
Daratumumab 1,800mg solution for subcutaneous injection (Darzalex®) SMC2301	In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. SMC restriction: in combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received one prior therapy only.	Available in line with national guidance	181	November 2020

Daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®) SMC2180	In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. SMC restriction: in combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received one prior therapy only.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	176	Oct 2019
Daratumumab 20 mg/mL concentrate for solution for infusion (Darzalex®) SMC2191	In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not available as not recommended for use in NHS Scotland	175	Aug 2019
Daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®) SMC No (1205/17)	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. SMC restriction: for use as a fourth line treatment option	Available in line with national guidance	159 164	Feb 2017 Nov 2017
Darbepoetin alfa (Aranesp®)	Cancer treatment induced anaemia	Not recommended	58	2006
Darbepoetin alfa (Aranesp®) SureClick	Cancer treatment induced anaemia	Not recommended	58	2006
Daridorexant film coated tablets (Quviviq) SMC2611	Treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	197	May/Jun 24
Darifenacin	Overactive bladder	Non-formulary	69	June 2007
Darolutamide 300mg film-coated tablets (Nubeqa®) SMC2604	treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.	Available in line with national guidance	195	December 2023

Darolutamide 300mg film-coated tablets (Nubeqa®) SMC2297	Darolutamide is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.	Available in line with national guidance	182	January 2021
Darolutamide 300mg film-coated tablets (Nubeqa®) SMC 2544	Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.	Not recommended		
Darunavir 800mg, cobicistat 150mg, emtricitabine 200mg, tenofovir alafenamide 10mg film-coated tablet (Symtuza®) SMC No 1290/18	The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg).	Available in line with National Guidance	167	April 2018
Darunavir (Prezista®) (1069/15)	Once daily darunavir co-administered with low dose ritonavir in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients aged 3 to 12 years and ≥15kg who are 1) treatment-naive or 2) treatment-experienced with no darunavir resistance-associated mutations, plasma-HIV-1 RNA <100,000 copies/mL, and CD4+ count >100x106 cells/L.	Formulary (Paediatric HIV clinic)	150	June 2015
Darunavir (Prezista®) (948/14)	HIV-1 infection in paediatric patients 12 to 17 years of age	HOSPITAL ONLY - (Paediatrics) Under direction of paediatric HIV specialist in Lothian or Glasgow	136	Mar/Apr 2014
Darunavir (Prezista®) (861/13)	HIV-1	HOSPITAL ONLY	127	May 2013
Darunavir (Prezista®) (707/11)	HIV-1	HOSPITAL ONLY (HIV Clinic)	109 95 92 69	Sept 2011 Feb/Mar 2010 Aug/Sept 2009 June 2007

Darunavir/cobicistat (Rezolsta®) (1081/15)	In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. Genotypic testing should guide its use.	Formulary Hospital only (HIV Clinic)	150 151	July 2015 Sep/Oct 2015
Darvadstrocel 30 million cells/6mL suspension for injection (Alofisel®) SMC2115	For the treatment of complex perianal fistulas in adult patients with non-active / mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.	Not available as not recommended for use in NHS Scotland	176	Oct 2019
Dasatinib 20mg / 50mg / 80mg / 100mg and 140mg film-coated tablets (Sprycel®) SMC2192	The treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.	Not available as not recommended for use in NHS Scotland	175	Aug 2019
Dasatinib 20mg, 50mg, 80mg, 100mg, 140 mg film-coated tablets (Sprycel®) SMC2142	For the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib	Available from a specialist centre in another NHS Board	174	May 2019
Dasatinib 20mg, 50mg, 80mg, 100mg and 140mg film-coated tablets (Sprycel®) SMC 1170/16	For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	157	Nov 2016
Dasatinib 20mg, 50mg, 80mg, 100mg and 140mg film-coated tablets (Sprycel®) SMC 371/07	For the treatment of adult patients with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	68 157	May 2007 Nov 2016
Dasatinib (Sprycel®) (370/07)	Chronic myeloid leukaemia (CML)	HOSPITAL ONLY	68	May 2007
Decitabine/cedazuridine film-coated tablets (Inaqovi®)	Indication under review: as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia		198 not yet published	

SMC2681	(AML) who are ineligible for standard induction chemotherapy.			
Decitabine (Dacogen®) (846/12)	AML	Not recommended	124	Feb 2013
Defatted powder of Arachis hypogaea L., semen (peanuts) 0.5mg, 1mg, 10mg, 20mg, 100mg oral powder in capsules for opening and 300mg oral powder in sachet (Palforzia®) SMC 2487	Treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia® may be continued in patients 18 years of age and older. Palforzia® should be used in conjunction with a peanut-avoidant diet. Palforzia®, compared with placebo, increased the proportion of patients aged 4 to 17 years with peanut allergy who could tolerate, with no more than mild symptoms, a single dose of at least 1,000mg peanut protein (2,043mg cumulative).	Not available as not recommended for use in NHS Scotland	191	Nov 2022
Deferasirox, 90mg, 180mg and 360mg film-coated tablets (Exjade®) SMC No (1246/17)	Treatment of chronic iron overload due to frequent blood transfusions (≥7mL/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups: - in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7mL/kg/month of packed red blood cells) aged 2 to 5 years, - in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7mL/kg/month of packed red blood cells) aged 2 years and older, - in adult and paediatric patients with other anaemias aged 2 years and older Restriction: deferasirox film-coated tablets are restricted to use as for the SMC advice issued for deferasirox dispersible tablets (No.347/07 - accepted for restricted use within NHS Scotland for the treatment of chronic iron overload associated with the treatment of rare acquired or inherited anaemias requiring recurrent blood transfusions. It is not recommended for patients with myelodysplastic syndromes).	Available in line with National Guidance	162	Aug 2017

Deferasirox 125mg, 250mg, 500mg dispersible tablets (Exjade®) SMC No. (347/07)	Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate, in adult and paediatric patients aged 2 years and older with rare acquired or inherited anaemias. The current advice relates only to use in the myelodysplastic syndrome (MDS) population. SMC Restriction: use in patients with MDS with an International Prognostic Scoring System (IPSS) score of low or intermediate -1 risk.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts – decision expected by April 2017	159	Feb 2017
Deferasirox (Exjade®) (866/13)	Chronic iron overload	Not recommended	127	May 2013
Deferasirox (Exjade®)	Chronic iron overload	HOSPITAL ONLY	66	Feb 2007
Defibrotide (Defitello®) (967/14)	Severe depatic veno-occlusive disease (VOD)	Non-formulary - absence of clinician demand	139	June/July 2014
Degarelix injection (Firmagon) SMC2625	• for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. • as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	196 – awaiting publication	February 2024
Degarelix (Firmagon®) (560/09)	Advanced hormone-dependent prostate cancer in adult male patients	GPs may prescribe under the direct of the Urology/ Oncology Clinic	108 103 102 92	Aug 2011 Feb/Mar 2011 Jan/Feb 2011 Aug/Sep 2009
Delafloxacin 450mg tablets and 300mg powder for concentrate for solution for infusion (Quofenix®) SMC2453	Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of this infection.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there	190	August 2022

		is a local preference for alternative medicines.		
Delta-9-tetrahydrocannabinol 2.7mg and cannabidiol 2.5mg per 100 microlitre spray (Sativex® Oromucosal Spray) SMC 2473	As treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.	Not routinely available as local implementation plans are being developed - decision expected by April 2023	191	Nov 2022
Denosumab 60mg solution for injection in pre-filled syringe (Prolia ®) SMC2117	Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.	Not available as not recommended for use in NHS Scotland	171	Oct 2018
Denosumab 120mg solution for injection (Xgeva ®) SMC No 2110	Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with haematological malignancies involving bone.	Not available as not recommended for use in NHS Scotland	170	Sep 2018
Denosumab (Prolia®) (1013/14)	Osteoporosis in men at increased risk of fractures	Not recommended	143	Nov/Dec 2014
Denosumab 120mg solution for injection (Xgeva®) SMC No. 1119/15	Adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity	Not recommended	153	Jan/Feb 2016
Denosumab (Xgeva®) (753/11)	Prevention of skeletal related events	Not recommended	113	Jan 2012
Denosumab (Prolia®) (651/10)	Osteoporosis in postmenopausal women	GPs may prescribe under the direction of the Osteoporosis Clinic or Medicines for the elderly	112 Protocol 104 101	Dec 2011 Mar 2011 Dec 10/Jan 2011
Denosumab (Prolia®) (670/10)	Bone loss associated with hormone ablation in men with	Not recommended	101	Dec 2010/Jan

	prostate cancer			2011
Dermatophagoides pteronyssinus and Dermatophagoides farinae oral lyophilisate (Acarizax®) SMC2613	Adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions: – persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication – house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment Adolescents (12-17 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.	Not available as not recommended for use in NHS Scotland	194	September 2023
Desmopressin (DDAVP Melt®) (358/07)	Diabetes insipidus		68	May 2007
Desmopressin (DesmoMelt®) (357/07)	Nocturnal enuresis	Non-formulary	68 60	May 2007 2006
Desmopressin 25 microgram, 50 microgram oral lyophilisate (Noqdirna®) SMC No. (1218/17)	Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. SMC restriction: For use in patients aged 65 years and over.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts	160 163	Apr 2017 Sep 2017
Desogestrel (Cerazette®)	Oestrogen free contraceptive		44 36	2003

			31 26	
Dequalininium chloride 10mg vaginal tablets (Fluomizin®) SMC 1194/16	Treatment of bacterial vaginosis. SMC restriction: In patients for whom the initial treatment is not effective or well tolerated	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines (Link to Formulary)	158	Dec 2016
Deucravacitinib film-coated tablets (Sotyktu) SMC2581	for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	196	February 2024
Dexamethasone 40mg tablets (Neofordex ®) SMC No 1322/18	In adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.	Not available as not recommended in NHS Scotland	168	May 2018
Dexamethasone (Ozurdex®) (1046/15)	For the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.	Non Formulary - lack of clinician support	148	May 2015
Dexamethasone implant (Ozurdex®) (751/11)	Adults with inflammation of the posterior segment of the eye	Not recommended	114	Feb 2012
Dexamethasone implant (Ozurdex®) (652/10)	Adults with macular oedema	Non-formulary - absence of clinician demand	119 118 113 101	Aug/Sept 2012 July 2012 Jan 2012 Dec 2010/Jan

				2011
Dexmedetomidine 100 micrograms/ml concentrate for solution for infusion (Dexdor®) SMC 2161	Sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation.	Not available as not recommended for use in NHS Scotland	174	May 2019
Dexmedetomidine (Dexdor®) (784/12)	Sedation in adult intensive care unit (ICU)	HOSPITAL ONLY (ICU)	118	July 2012
Dexrazoxane (Cardioxane®) (419/07)	Chronic cumulative cardiotoxicity	Not recommended	74	Nov 2007
Dexrazoxane (Savene®) (361/07)	Anthracycline extravasation	Not recommended	83 68	Oct 2008 May 2007
Diamorphine hydrochloride 720 microgram/actuation and 1600 microgram/actuation nasal spray (Ayendi®) SMC (1172/16)	Treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphone hydro-chloride nasal spray should be administered in the emergency setting by practitioners experienced in the administration of opioids in children with appropriate monitoring.	Available in line with national guidance Hospital only (A&E)	156 157 160	Sep 2016 Nov 2016 Apr 2017
Dibotermin alfa (InductOs®) (365/07)	Acute tibia fractures in adults	Not recommended	68	May 2007
Diclofenac 4% spray gel Mobigel Spray®) (667/10)	Local symptomatic relief of mild to moderate pain and inflammation	Not recommended	101	Dec 10/Jan 2011
Diclofenac 75mg/2ml injection (Dyloject®) (446/08)	Prevention of post-operative pain	HOSPITAL ONLY	77	Mar 2008
Diclofenac gel patch (Voltarol®)	Epicondylitis and ankle sprain	Not recommended	54	2005
Difelikefalin solution for injection (Kapruvia®) SMC2623	Treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	197 – Awaiting publication	Apr 2024

Dimethyl fumarate 30mg and 120mg gastro-resistant tablets (Skilarence®) SMC No 1313/18	For the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. SMC restriction: for use in patients in whom other non-biologic systemic treatments (methotrexate, ciclosporin and acitretin) are not appropriate or have failed and who are considered unsuitable for biologic therapy given their current disease state or personal preference.	Available in line with national guidance	168	May 2018
Dimethyl fumarate (Tecfidera®) (886/13)	Treatment of adult patients with relapsing remitting multiple sclerosis	Available in line with local guidance for prescribing	137	Apr/May 2014
Dinoprostone (Propess®)	Cervical ripening	HOSPITAL ONLY	60	2006
Dinutuximab beta 4.5mg/mL concentrate for solution for infusion (Qarziba®) SMC2105	For the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures.	Available from a specialist centre in another NHS Board	172	Dec 2018
Diroximel fumarate 231mg gastro-resistant hard capsules (Vumerity®) SMC2444	Treatment of adult patients with relapsing remitting multiple sclerosis. Diroximel fumarate provides an additional treatment choice in the therapeutic class of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	188	April 2022
Docetaxel (Taxotere®)	Unresectable locally advanced or metastatic (Stage III/IV) NSCLC		26	2003
Docetaxel (Taxotere®) (201/05)	Adjuvant treatment of operable, node +ve breast cancer	HOSPITAL ONLY (Oncology)	108 Protocol 100	Aug 2011 Oct/Nov 2010

			54	2005
Docetaxel (Taxotere®)	Hormone refractory metastatic prostate cancer (mHRPC)	HOSPITAL ONLY (Oncology)	108 Protocol 60 54	Aug 2011 2006 2005
Docetaxel (Taxotere®)	Metastatic gastric adenocarcinoma	Not recommended	63	2006
Docetaxel (Taxotere®) (369/07)	Induction chemotherapy in advanced squamous cell carcinoma of the head and neck (SCCHN)	Non-formulary - absence of clinician support	116 68	Apr/May 2012 May 2007
Docetaxel (Taxotere®) (481/08)	Induction treatment of patients with resectable locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and 5-fluorouracil	Non-formulary - pending protocol update	116 81	Apr/May 2012 July 2008
Dolutegravir 50mg / lamivudine 300mg film-coated tablets (Dovato®) SMC2205	For the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.	Available in line with local guidance for prescribing (HIV clinic only)	177	Dec 2019
Dolutegravir 50mg / rilpivirine 25mg film-coated tablets (Juluca®) SMC2091	The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor. Dolutegravir plus rilpivirine was shown to be non-inferior to antiretroviral regimens containing a dual nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone plus a third agent (integrase inhibitor, protease inhibitor or NNRTI in maintaining plasma HIV-1 RNA <50 copies/mL in two phase III randomised studies in virologically-suppressed adults.	Available in line with national guidance	171	Oct 2018
Dolutegravir (Triumeq®) (1009/14)	HIV	Formulary - HOSPITAL ONLY (HIV Clinic)	144	Jan/Feb 2015
Dolutegravir 10mg, 25mg, 50mg	in combination with other anti-retroviral medicinal products for	Available in line with national	163	Sep 2017

film-coated tablets (Tivicay®) SMC No. (1253/17)	the treatment of Human Immunodeficiency Virus (HIV) infected children aged >6 to 12 years of age. SMC has previously accepted dolutegravir 50mg film-coated tablets for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age	guidance		
Dolutegravir (Tivicay®) (961/14)	HIV infected adults and adolescents above 12 years of age	HOSPITAL ONLY (HIV Service)	138	May/June 2014
Donanemab concentrate for solution for infusion (Kisunla®) SMC2687	For the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (apoe ε4) heterozygotes or non-carriers. In a randomised, double-blind, phase III study, donanemab reduced cognitive and functional decline associated with early Alzheimer's disease compared with placebo at 76 weeks.	Not available as not recommended for use in NHS Scotland		
Donepezil orodispersible (Aricept Evess®)	Mild to moderately severe Alzheimer's dementia		66	Feb 2007
Doravirine/lamivudine/tenofovir disoproxil fumarate 100mg/300mg/245mg film-coated tablets (Delstrigo®) SMC2333	For the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir. Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) offers an additional treatment choice of NNRTI-based single-tablet regimen for this indication.	Available in line with local guidance for prescribing	184	May 2021
Doravirine 100mg film-coated tablets (Pifeltro®) SMC2332	In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.	Available in line with local guidance for prescribing	184	May 2021

	Doravirine offers an additional treatment choice in the therapeutic class of NNRTIs for this indication.			
Doravirine 100mg / lamivudine 300mg / tenofovir disoproxil 245mg film-coated tablets (Delstrigo®) SMC 2163	Treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class, lamivudine, or tenofovir.	Not available as not recommended for use in NHS Scotland	174	May 2019
Doravirine 100mg film-coated tablets (Pifeltro®) SMC 2162	In combination with other antiretroviral medicinal products, for the treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class.	Not available as not recommended for use in NHS Scotland	174	May 2019
Doripenem (Doribax®)	Nosocomial pneumonia		89 87	May 2009 March 2008
Doripenem (Doribax®) (529/09)	Complicated intra-abdominal infections in adults	Not recommended	89 86	May 2009 Jan 2009
Dorzolamide (Trusopt®) unit dose eye drops	Ocular hypertension, glaucoma		59	2006
Dorzolamide 2%/timolol maleate 0.5% (Cosopt®) unit dose eye drops	Glaucoma	Non-formulary	65	Jan 2007
Dostarlimab concentrate for solution for infusion (Jemperli) GlaxoSmithKline SMC2635	In combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Available in line with national guidance	197	May/June 2024
Dostarlimab 500mg concentrate for solution for infusion (Jemperli®) SMC2404	As monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	188	April 2022

Doxylamine succinate 10mg and pyridoxine hydrochloride 10mg gastro-resistant tablets (Xonvea®) SMC2140	The treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Doxylamine in combination with pyridoxine significantly improved symptoms of nausea and vomiting compared with placebo in women with nausea and vomiting of pregnancy.	Not available as not recommended for use in NHS Scotland	175	Aug 2019
Dronedarone (Multaq®)	Non-permanent atrial fibrillation (AF)	Specialist formulary list (Cardiology) - HOSPITAL ONLY	113 110 Protocol 99	Jan 2012 Oct 2011 Aug/Sept 2010
Droperidol 2.5mg/mL solution for injection	PONV in adults	HOSPITAL ONLY - Acute Pain Specialist formulary list	123 93	Jan 2013 Oct/Nov 2009
Drospirenone/ ethinylestradiol (Yasmin®) (23/03)	Combined oral contraceptive	Not recommended	105 25	April/May 2011 2003
Drotrecogin alfa (activated) (Xigris®) *Withdrawn October 2011	Severe sepsis	Withdrawn	21	2002
Dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity®) SMC No. 1110/15	In adults with type 2 diabetes mellitus to improve glycaemic control	Available in line with local guidance for prescribing	153 154	Jan/Feb 2016 May 2016
Duloxetine (Cymbalta®) (514/08)	Generalised anxiety disorder	Not recommended	83	Oct 2008
Duloxetine (Cymbalta®)	Diabetic peripheral neuropathic pain (DPNP)	Non-formulary	61	2006
Duloxetine (Cymbalta®)	Major depressive episodes	Formulary (Mental Health specialist list)	117 53	May/June 2012 2005
Duloxetine (Yentreve®)	Stress incontinence		45	2004
Dupilumab solution for injection	Indication under review: treatment of eosinophilic esophagitis	Not recommended for use in	198 not yet	

in pre-filled pen and syringe (Dupixent) SMC2682	in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy	NHS Scotland	published	
Dupilumab 200mg and 300mg solution for injection in pre-filled syringe and pen (Dupixent®) SMC2317	Indication under review: in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. SMC restriction: for the treatment of patients with blood eosinophils ≥150 cells/microlitre and FeNO ≥25 parts per billion, and ≥4 exacerbations in the preceding year, who have previously received biologic treatment with anti-IgE or anti-IL-5 therapies. In a phase III study dupilumab, compared with placebo, reduced asthma exacerbation rates and was associated with greater improvements in lung function, in patients with asthma uncontrolled with medium to high dose ICS plus one or two controller medicines.	available in line with national guidance	184	May 2021
Dupilumab 300mg solution for injection in pre-filled pen and 300mg solution for injection in pre-filled syringe (Dupixent®) SMC2324	Indication under review: As an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control	Not available as not recommended for use in NHS Scotland	183	Awaiting publication
Dupilumab 200mg and 300mg solution for injection in pre-filled syringe (Dupixent®) SMC 2232	The treatment of moderate-to-severe atopic dermatitis in adolescents (≥12 to <18 years) who are candidates for systemic therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or	179	Apr 2020

		there is a local preference for alternative medicines.		
Dupilumab 300mg solution for injection in pre-filled syringe (Dupixent®) SMC2011	The treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. SMC restriction: patients who have had an inadequate response to existing systemic immunosuppressants such as ciclosporin, or in whom such treatment is considered unsuitable.	Available in line with local guidance for prescribing	171	Oct 2018
Dupilumab 300 mg solution for injection in pre-filled syringe or pre-filled pen (Dupixent®) SMC2598	For the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.	Available in line with local guidance	197 – Awaiting publication	Apr 2024
durvalumab concentrate for solution for infusion (Imfinzi®) SMC2735	In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). In an open-label phase III study durvalumab in combination with tremelimumab was associated with statistically significant improvements in overall survival compared with a multikinase inhibitor.	Not available as not recommended for use in NHS Scotland		
Durvalumab 50 mg/ml concentrate for solution for infusion (Imfinzi®) SMC2734	In combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). Durvalumab offers an additional treatment choice in the therapeutic class of PD-1 / PD-L1 (Programmed cell death protein 1 / death ligand 1) inhibitors. Another PD-1 / PD-L1 inhibitor was accepted for use under the	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		

	end of life and orphan process.			
Durvalumab concentrate for solution for infusion (Imfinzi®) SMC2677	In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known EGFR mutations or ALK rearrangements In a randomised, double-blind, phase III study, the addition of neoadjuvant and adjuvant durvalumab compared with the addition of placebo to neoadjuvant chemotherapy significantly improved complete pathological response and event-free survival in patients with resectable NSCLC.	Not available as not recommended for use in NHS Scotland		
Durvalumab concentrate for solution for infusion (Imfinzi®) SMC2582	In combination with gemcitabine and cisplatin for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer.	Available in line with national guidance	195	December 2023
durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®) SMC2434		Not available as not recommended for use in NHS Scotland	188	April 2022
Durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®) SMC2156	As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.	Available in line with local guidance for prescribing.	175	Aug 2019
Dutasteride (Combodart®) (628/10)	BPH	Non-formulary	101 100	Dec 2010/Jan 2011 Oct/Nov 2010 Aug/Sept

			99	2010
Dutasteride (Avodart®)	BPH		44 26	2003

Updated: 9th June 2025

Back to top Back to homepage